- Home
- PTCT
as of 12-16-2025 3:40pm EST
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 5.3B | IPO Year: | 2013 |
| Target Price: | $73.76 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.95 - $87.50 | Next Earning Date: | 11-04-2025 |
| Revenue: | $1,779,150,000 | Revenue Growth: | 97.54% |
| Revenue Growth (this year): | 128.32% | Revenue Growth (next year): | -45.49% |
AI-Powered PTCT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$79.07
Shares
3,428
Total Value
$271,051.96
Owned After
349,964
SEC Form 4
Director
Avg Cost/Share
$84.00
Shares
14,199
Total Value
$1,186,282.29
Owned After
22,891
CHIEF TECHNICAL OPS OFFICER
Avg Cost/Share
$83.89
Shares
71,928
Total Value
$6,001,932.05
Owned After
100,625
Director
Avg Cost/Share
$80.14
Shares
11,801
Total Value
$945,736.13
Owned After
22,891
CHIEF TECHNICAL OPS OFFICER
Avg Cost/Share
$80.16
Shares
35,572
Total Value
$2,852,030.56
Owned After
100,625
Director
Avg Cost/Share
$79.50
Shares
10,000
Total Value
$795,000.00
Owned After
6,666
SEC Form 4
EXEC. VP AND CLO
Avg Cost/Share
$76.45
Shares
2,812
Total Value
$213,686.89
Owned After
103,901
Director
Avg Cost/Share
$74.50
Shares
7,333
Total Value
$546,308.50
Owned After
6,666
SEC Form 4
Director
Avg Cost/Share
$69.50
Shares
15,666
Total Value
$1,088,787.00
Owned After
6,666
EXEC. VP AND CLO
Avg Cost/Share
$63.89
Shares
3,375
Total Value
$214,091.17
Owned After
103,901
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Dec 2, 2025 | Sell | $79.07 | 3,428 | $271,051.96 | 349,964 | |
| Jacobson Allan Steven | PTCT | Director | Nov 25, 2025 | Sell | $84.00 | 14,199 | $1,186,282.29 | 22,891 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Nov 25, 2025 | Sell | $83.89 | 71,928 | $6,001,932.05 | 100,625 | |
| Jacobson Allan Steven | PTCT | Director | Nov 24, 2025 | Sell | $80.14 | 11,801 | $945,736.13 | 22,891 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Nov 24, 2025 | Sell | $80.16 | 35,572 | $2,852,030.56 | 100,625 | |
| Reeve Emma | PTCT | Director | Nov 21, 2025 | Sell | $79.50 | 10,000 | $795,000.00 | 6,666 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Nov 17, 2025 | Sell | $76.45 | 2,812 | $213,686.89 | 103,901 | |
| Reeve Emma | PTCT | Director | Nov 12, 2025 | Sell | $74.50 | 7,333 | $546,308.50 | 6,666 | |
| Reeve Emma | PTCT | Director | Oct 30, 2025 | Sell | $69.50 | 15,666 | $1,088,787.00 | 6,666 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Oct 7, 2025 | Sell | $63.89 | 3,375 | $214,091.17 | 103,901 |
Compare PTCT vs Leading Stocks
See how PTCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.